158 related articles for article (PubMed ID: 36190930)
1. Targeting Tumor Hypoxia Inhibits Aggressive Phenotype of Dedifferentiated Thyroid Cancer.
Ma B; Wen S; Luo Y; Zhang T; Yang Y; Shen C; Zhang Y; Ji Q; Qu N; Wang Y
J Clin Endocrinol Metab; 2023 Jan; 108(2):368-384. PubMed ID: 36190930
[TBL] [Abstract][Full Text] [Related]
2. Cancer-Associated Fibroblasts Positively Correlate with Dedifferentiation and Aggressiveness of Thyroid Cancer.
Wen S; Qu N; Ma B; Wang X; Luo Y; Xu W; Jiang H; Zhang Y; Wang Y; Ji Q
Onco Targets Ther; 2021; 14():1205-1217. PubMed ID: 33654411
[TBL] [Abstract][Full Text] [Related]
3. LINC00886 Negatively Regulates Malignancy in Anaplastic Thyroid Cancer.
Ma B; Luo Y; Xu W; Han L; Liu W; Liao T; Yang Y; Wang Y
Endocrinology; 2023 Feb; 164(4):. PubMed ID: 36726346
[TBL] [Abstract][Full Text] [Related]
4. Transcriptome Analyses Identify a Metabolic Gene Signature Indicative of Dedifferentiation of Papillary Thyroid Cancer.
Ma B; Jiang H; Wen D; Hu J; Han L; Liu W; Xu W; Shi X; Wei W; Liao T; Wang Y; Lu Z; Wang Y; Ji Q
J Clin Endocrinol Metab; 2019 Sep; 104(9):3713-3725. PubMed ID: 30942873
[TBL] [Abstract][Full Text] [Related]
5. Diallyl trisulphide, a H
Zhang L; Xu S; Cheng X; Zheng J; Wang Y; Wu J; Wang X; Wu L; Yu H; Bao J
Phytother Res; 2021 Jun; 35(6):3428-3443. PubMed ID: 33751676
[TBL] [Abstract][Full Text] [Related]
6. A 4 Gene-based Immune Signature Predicts Dedifferentiation and Immune Exhaustion in Thyroid Cancer.
Li CW; Shi X; Ma B; Wang YL; Lu ZW; Liao T; Wang Y; Ji QH; Wei WJ
J Clin Endocrinol Metab; 2021 Jul; 106(8):e3208-e3220. PubMed ID: 33656532
[TBL] [Abstract][Full Text] [Related]
7. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
8. Novel Anaplastic Thyroid Cancer PDXs and Cell Lines: Expanding Preclinical Models of Genetic Diversity.
Maniakas A; Henderson YC; Hei H; Peng S; Chen Y; Jiang Y; Ji S; Cardenas M; Chiu Y; Bell D; Williams MD; Hofmann MC; Scherer SE; Wheeler DA; Busaidy NL; Dadu R; Wang JR; Cabanillas ME; Zafereo M; Johnson FM; Lai SY
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4652-e4665. PubMed ID: 34147031
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-11 promotes epithelial-mesenchymal transition in anaplastic thyroid carcinoma cells through PI3K/Akt/GSK3β signaling pathway activation.
Zhong Z; Hu Z; Jiang Y; Sun R; Chen X; Chu H; Zeng M; Sun C
Oncotarget; 2016 Sep; 7(37):59652-59663. PubMed ID: 27487122
[TBL] [Abstract][Full Text] [Related]
10. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
11. CSPG4 Is a Potential Therapeutic Target in Anaplastic Thyroid Cancer.
Egan CE; Stefanova D; Ahmed A; Raja VJ; Thiesmeyer JW; Chen KJ; Greenberg JA; Zhang T; He B; Finnerty BM; Zarnegar R; Jin MM; Scognamiglio T; Dephoure N; Fahey T; Min IM
Thyroid; 2021 Oct; 31(10):1481-1493. PubMed ID: 34078123
[No Abstract] [Full Text] [Related]
12. Integrated analysis of novel macrophage related signature in anaplastic thyroid cancer.
Luo Y; Yang YC; Ma B; Xu WB; Liao T; Wang Y
Endocrine; 2022 Dec; 78(3):517-530. PubMed ID: 36070052
[TBL] [Abstract][Full Text] [Related]
13. Establishment and characterization of a new patient-derived anaplastic thyroid cancer cell line (C3948), obtained through fine-needle aspiration cytology.
Pinto AT; Pojo M; Simões-Pereira J; Roque R; Saramago A; Roque L; Martins C; André S; Cabeçadas J; Leite V; Cavaco BM
Endocrine; 2019 Nov; 66(2):288-300. PubMed ID: 31368081
[TBL] [Abstract][Full Text] [Related]
14. Targeting CD47 in Anaplastic Thyroid Carcinoma Enhances Tumor Phagocytosis by Macrophages and Is a Promising Therapeutic Strategy.
Schürch CM; Roelli MA; Forster S; Wasmer MH; Brühl F; Maire RS; Di Pancrazio S; Ruepp MD; Giger R; Perren A; Schmitt AM; Krebs P; Charles RP; Dettmer MS
Thyroid; 2019 Jul; 29(7):979-992. PubMed ID: 30938231
[No Abstract] [Full Text] [Related]
15. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
16. Targeting Super-Enhancer-Driven Oncogenic Transcription by CDK7 Inhibition in Anaplastic Thyroid Carcinoma.
Cao X; Dang L; Zheng X; Lu Y; Lu Y; Ji R; Zhang T; Ruan X; Zhi J; Hou X; Yi X; Li MJ; Gu T; Gao M; Zhang L; Chen Y
Thyroid; 2019 Jun; 29(6):809-823. PubMed ID: 30924726
[No Abstract] [Full Text] [Related]
17. REGγ ablation impedes dedifferentiation of anaplastic thyroid carcinoma and accentuates radio-therapeutic response by regulating the Smad7-TGF-β pathway.
Jiao C; Li L; Zhang P; Zhang L; Li K; Fang R; Yuan L; Shi K; Pan L; Guo Q; Gao X; Chen G; Xu S; Wang Q; Zuo D; Wu W; Qiao S; Wang X; Moses R; Xiao J; Li L; Dang Y; Li X
Cell Death Differ; 2020 Feb; 27(2):497-508. PubMed ID: 31243343
[TBL] [Abstract][Full Text] [Related]
18. GDC-0941 inhibits metastatic characteristics of thyroid carcinomas by targeting both the phosphoinositide-3 kinase (PI3K) and hypoxia-inducible factor-1α (HIF-1α) pathways.
Burrows N; Babur M; Resch J; Ridsdale S; Mejin M; Rowling EJ; Brabant G; Williams KJ
J Clin Endocrinol Metab; 2011 Dec; 96(12):E1934-43. PubMed ID: 21994956
[TBL] [Abstract][Full Text] [Related]
19. Integrative analysis of genomic and transcriptomic characteristics associated with progression of aggressive thyroid cancer.
Yoo SK; Song YS; Lee EK; Hwang J; Kim HH; Jung G; Kim YA; Kim SJ; Cho SW; Won JK; Chung EJ; Shin JY; Lee KE; Kim JI; Park YJ; Seo JS
Nat Commun; 2019 Jun; 10(1):2764. PubMed ID: 31235699
[TBL] [Abstract][Full Text] [Related]
20. JAK/STAT3 and NF-κB Signaling Pathways Regulate Cancer Stem-Cell Properties in Anaplastic Thyroid Cancer Cells.
Shiraiwa K; Matsuse M; Nakazawa Y; Ogi T; Suzuki K; Saenko V; Xu S; Umezawa K; Yamashita S; Tsukamoto K; Mitsutake N
Thyroid; 2019 May; 29(5):674-682. PubMed ID: 30784360
[No Abstract] [Full Text] [Related]
[Next] [New Search]
